Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kazem Hak

Internal Medicine Flint, MI Medical Doctor

NPI 1083688725 CMS profile 321550

3400 Fleckenstein Rd, Suite 3, Flint, MI 48507

Open in the dashboard

General payments

$11,866

756 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kazem Hak of Flint, MI is reported in the CMS Open Payments database as having received $11,866 across 756 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $124 1
2024 General $2,264 118
2023 General $2,895 158
2022 General $2,123 147
2021 General $1,340 83
2020 General $910 73
2019 General $2,211 176

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kazem Hak
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kazem Hak were reported at $124. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kazem Hak Internal Medicine median Middle half National median
2019 $2,211 $159 $48–$570 $163
2020 $910 $119 $33–$402 $114
2021 $1,340 $135 $37–$521 $132
2022 $2,123 $141 $42–$496 $149
2023 $2,895 $149 $45–$519 $160
2024 $2,264 $154 $47–$537 $164
2025 $124 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,591 62 payments
  2. GlaxoSmithKline, LLC. $1,568 66 payments
  3. Novo Nordisk Inc $1,376 141 payments
  4. AbbVie, Inc. $815 67 payments
  5. Merck Sharp & Dohme Corporation $660 53 payments
  6. Amgen Inc. $460 36 payments
  7. Novartis Pharmaceuticals Corporation $389 24 payments
  8. Pfizer Inc. $346 25 payments
  9. Nestle HealthCare Nutrition Inc. $322 27 payments
  10. Lilly USA, LLC $312 20 payments
  11. Other $4,027 235 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,694 752 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150 1 payment
  3. Education $22 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,064 26 payments
  2. BREZTRI $823 26 payments
  3. Ozempic $720 72 payments
  4. TRELEGY ELLIPTA $659 42 payments
  5. RYBELSUS $625 54 payments
  6. VERQUVO $440 26 payments
  7. SYMBICORT $418 12 payments
  8. UBRELVY $398 25 payments
  9. ZENPEP $376 30 payments
  10. STEGLATRO $361 34 payments
  11. Other $10,573 664 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 224 drugs

Part D claims

18,698

Median for Internal Medicine: 777

Drug cost

$2,218,082

Median for Internal Medicine: $73,373

Branded share of claims

24.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 281 $283,501
Rybelsus Semaglutide Brand 119 $207,486
Mounjaro Tirzepatide Brand 135 $188,519
Xarelto Rivaroxaban Brand 103 $141,073
Jardiance Empagliflozin Brand 100 $132,471
Ozempic Semaglutide Brand 103 $116,862
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 110 $111,181
Rexulti Brexpiprazole Brand 41 $77,341
Trulicity Dulaglutide Brand 46 $70,282
Januvia Sitagliptin Phosphate Brand 38 $57,277

The 10 drugs with the highest cost, of 224 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$93,451

Of which drugs: $4,126

Medicare patients

254

Average age 75

Services billed

1,525

136 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 33%
Ischemic heart disease 27%
Heart failure 20%
Atrial fibrillation 20%
Depression 19%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 53 53 $3,747
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 286 $190

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
$171 26 —
UBRELVY
$152 — —
AREXVY
$134 — —
VERQUVO
$102 — —
AIRSUPRA
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

756 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record